

Our Ref: 515/2023  
October 2023

## **Re: Your request made under the Freedom of Information Act 2000**

I am analysing the usage of new biologic and targeted medications within dermatology and respiratory medicine. Could you please answer the following questions:

Q1. How many patients were treated in September 2023 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo) - 0
- Baricitinib (Olumiant) - 4
- Dupilumab (Dupixent) - 11
- Omalizumab (Xolair) - 0
- Tralokinumab (Adtralza) - 0
- Upadacitinib (Rinvoq) - 0

Q2. How many patients were treated in September 2023 (or latest available month) by the Respiratory Medicine department with the following drugs:

- Benralizumab (Fasenra) - 5
- Dupilumab (Dupixent) - 12
- Mepolizumab (Nucala) - 13
- Omalizumab (Xolair) - 2
- Reslizumab (Cinqaero) - 0
- Tezepelumab (Tezspire) - 0